After long wait, Editas reveals first data for CRISPR gene editing treatment
Bio Pharma Dive
SEPTEMBER 29, 2021
Early study results offer some hopeful signs of efficacy, but the small number of patients treated and short follow-up limit firmer conclusions.
Let's personalize your content